{"nctId":"NCT02412111","briefTitle":"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor","startDateStruct":{"date":"2015-06","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":156,"armGroups":[{"label":"Ivacaftor (Run-in Period)","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor"]},{"label":"VX-661 + Ivacaftor (Active comparator period)","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor","Drug: Tezacaftor/Ivacaftor"]},{"label":"Ivacaftor monotherapy (Active comparator period)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ivacaftor"]}],"interventions":[{"name":"Ivacaftor","otherNames":["VX-770"]},{"name":"Tezacaftor/Ivacaftor","otherNames":["VX-661/VX-770"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive\n* FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height during screening\n* Stable CF disease as judged by the investigator.\n\nExclusion Criteria:\n\n* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.\n* Pregnant and nursing females (females of childbearing potential must have a negative pregnancy test at Screening and Week -4 Visits).\n* Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.4"},{"groupId":"OG001","value":"0.2","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.6"},{"groupId":"OG001","value":"0.5","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 8","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.3"},{"groupId":"OG001","value":"-2.1","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Sweat Chloride Through Week 8","description":"Sweat samples were collected using an approved collection device.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","spread":"1.7"},{"groupId":"OG001","value":"-2.1","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"812","spread":"615"},{"groupId":"OG001","value":"1000","spread":"742"},{"groupId":"OG002","value":"740","spread":"464"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1590","spread":"956"},{"groupId":"OG001","value":"1830","spread":"1010"},{"groupId":"OG002","value":"1450","spread":"828"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2520","spread":"1490"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4870","spread":"1750"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":156},"commonTop":["Cough","Headache","Sputum increased","Infective pulmonary exacerbation of cystic fibrosis","Fatigue"]}}}